A modified toxicity probability interval method for dose-finding trials

Clinical Trials

Volumn 7, Issue 6, 2010, Pages 653-663

  Ji, Yuan ^a   Liu, Ping ^a   Li, Yisheng ^a   Bekele, B Nebiyou ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BAYESIAN LEARNING; CALIBRATION; COMPUTER PROGRAM; CONCEPTUAL FRAMEWORK; DOSE CALCULATION; MAXIMUM TOLERATED DOSE; METHODOLOGY; PERFORMANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROBABILITY; SENSITIVITY ANALYSIS; SIMULATION; STUDY DESIGN; TOXICITY PROBABILITY INTERVAL;

ALGORITHMS; BAYES THEOREM; CLINICAL TRIALS AS TOPIC; DRUG TOXICITY; HUMANS; MAXIMUM TOLERATED DOSE; MODELS, STATISTICAL; MODELS, THEORETICAL; PROBABILITY; STATISTICS AS TOPIC;

EID: 78650322746     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774510382799     Document Type: Article

References (19)

1. O'Quigley J., Pepe M., Fisher L. Continual reassessment method: a practical design for phase i clinical trials in cancer. Biometrics 1990 ; 46: 33-48.
2. Babb J., Rogatko A., Zacks S. Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat Med 1998 ; 17: 1103-20.
3. Cheung YK, Chappell R. Sequential designs for phase i clinical trials with lateonset toxicities. Biometrics 2000 ; 56: 1177-82.
4. Piantadosi S., Fisher JD, Grossman S. Practical implementation of a modified continual reassessment method for dose-finding trials. Cancer Chemother Pharmacol 1998 ; 41: 429-36.
5. Shen LZ, O'Quigley J. Consistency of continual reassessment method under model misspecification. Biometrika 1996 ; 83: 395-405.
6. Yuan Z., Chappell R., Bailey H. The continual reassessment method for multiple toxicity grades: A Bayesian quasi-likelihood approach. Biometrics 2007 ; 63: 173-79.
7. Thall PF, Lee S. -J. Practical model-based dose-finding in phase I clinical trials: Methods based on toxicity. Int J Gynecol Cancer 2003 ; 13: 251-61.
8. Lee SM, Cheung YK Model calibration in the continual reassessment method. Clin Trials 2009 ; 6: 227-38.
9. Ji Y., Li Y., Bekele BN Dose-finding in phase I clinical trials based on toxicity probability intervals. Clin Trials 2007 ; 4: 235-44.
10. Stylianou M., Flournoy N. Dose finding using the biased coin up-and-down design and isotonic regression. Biometrics 2002 ; 58: 171-77.
11. Ji Y., Li Y., Yin G. Bayesian dose-finding in phase I clinical trials based on a new statistical framework. Stat Sinica 2007 ; 17: 531-47.
12. Li Q., Tsui K-W., Ji Y. The choice of prior distribution in dose-finding of phase I clinical trials. Technical Report. Available at: http://odin.mdacc. tmc.edu/ylji/prior.pdf/,2010.
13. Goodman SN, Zahurak ML, Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Stat Med 1995 ; 14: 1149-61.
14. Garrett-Mayer E. The continual reassessment method for dose-finding studies: a tutorial. Clin Trials 2006 ; 3: 57-71.
15. Iasonos A., Wilton AS, Riedel ER, et al. A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in phase i dose-finding studies. Clin Trials 2008 ; 5: 465-77.
16. Zohar S., O'Quigley J. Sensitivity of dose-finding studies to observation errors. Contemp Clin Trials 2009 ; 30: 523-30.
17. Carlin BP, Louis TA Bayes and Empirical Bayes Methods for Data Analysis (2 nd edn). Chapman & Hall/CRC, Boca Raton, Florida, 2000.
18. Sen PK, Singer JM Large Sample Methods in Statistics. Chapman & Hall/CRC, Boca Raton, Florida, 1993.
19. Gelman A., Carlin JB, Stern HS, Rubin DB Bayesian Data Analysis. Chapman & Hall / CRC, Boca Raton, Florida, 1995.